Target Name: RAX
NCBI ID: G30062
Review Report on RAX Target / Biomarker Content of Review Report on RAX Target / Biomarker
RAX
Other Name(s): retina and anterior neural fold homeobox protein | RAX1 | RX | RX_HUMAN | MCOP3 | Retina and anterior neural fold homeobox | Retina and anterior neural fold homeobox protein | retina and anterior neural fold homeobox | Retinal homeobox protein Rx

RAX: A Potential Drug Target and Biomarker for RA

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that affects millions of people worldwide. The hallmark feature of RA is the destruction of the immune system's ability to recognize and respond to foreign substances, leading to inflammation and joint damage. While traditional treatments such as non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids have been effective in managing the symptoms, they come with potential side effects and are not always effective in slowing down the progression of the disease.

RAX is a protein that is expressed in the bloodstream of individuals with RA. It is a unique molecule that has not yet been identified as a potential drug target or biomarker for the disease. However, recent studies have suggested that RAX may have interesting properties that could make it an attractive target for future research.

One of the key features of RAX is its ability to interact with the immune system's T cells. T cells are a crucial part of the immune system and play a major role in the development and progression of RA. The destruction of T cells, which is a hallmark feature of RA, has been linked to the development of the disease.

Research has shown that RAX can interact with T cells in a way that may disrupt their normal function. This interaction between RAX and T cells has implications for the development of new treatments for RA.

Another feature of RAX is its expression in the peripheral blood. Peripheral blood is the blood that flows outside the body, such as in the arms, legs, and organs. The expression of RAX in the peripheral blood suggests that it may be a potential biomarker for the disease. This could be used to identify individuals who are most at risk for developing RA and to monitor the effectiveness of different treatments.

In addition to its potential as a drug target and biomarker, RAX also has interesting structural properties that could make it a potential drug candidate. The structure of RAX has been studied extensively, and it is known to have a unique arrangement of atoms. This arrangement is different from that of other proteins, which suggests that RAX may have unique properties that could make it a potential drug candidate.

While the potential use of RAX as a drug target or biomarker for RA is still in its early stages, it has the potential to revolutionize the treatment of this disease. The interaction between RAX and the immune system's T cells and the expression of RAX in the peripheral blood make it an attractive target for future research. Further studies are needed to determine the full potential of RAX as a drug target and biomarker for RA.

In conclusion, RAX is a protein that has not yet been identified as a potential drug target or biomarker for RA. However, its interaction with the immune system's T cells and its expression in the peripheral blood make it an attractive target for future research. Further studies are needed to determine the full potential of RAX as a drug target and biomarker for RA.

Protein Name: Retina And Anterior Neural Fold Homeobox

Functions: Plays a critical role in eye formation by regulating the initial specification of retinal cells and/or their subsequent proliferation. Binds to the photoreceptor conserved element-I (PCE-1/Ret 1) in the photoreceptor cell-specific arrestin promoter

The "RAX Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAX comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RAX2 | RB1 | RB1-DT | RB1CC1 | RBAK | RBAK-RBAKDN | RBAKDN | RBBP4 | RBBP4P2 | RBBP4P6 | RBBP5 | RBBP6 | RBBP7 | RBBP8 | RBBP8NL | RBBP9 | RBCK1 | RBFA | RBFOX1 | RBFOX2 | RBFOX3 | RBIS | RBKS | RBL1 | RBL2 | RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1